As discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements,” the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss).

The following tables present a summary of the corrections to the impacted financial statement line items in the Company’s financial statements previously issued in the Annual Report on Form 10-K and unaudited Quarterly Reports on Form 10-Q (in thousands):


	Twelve Months Ended December 31, 2024						Twelve Months Ended December 31, 2023
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	382,564	$	17,389	$	399,953	$	382,295	$	15,430	$	397,725
Gross profit	870,873		(17,389)		853,484		771,250		(15,430)		755,820
Selling, general, and administrative	526,265		(17,389)		508,876		518,129		(15,430)		502,699


	Three Months Ended March 31, 2025						Three Months Ended March 31, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	96,080	$	4,521	$	100,601	$	87,522	$	4,182	$	91,704
Gross profit	220,775		(4,521)		216,254		207,390		(4,182)		203,208
Selling, general, and administrative	133,667		(4,521)		129,146		129,863		(4,182)		125,681


	Three Months Ended June 30, 2024						Six Months Ended June 30, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	99,710	$	3,987	$	103,697	$	187,232	$	8,169	$	195,401
Gross profit	218,865		(3,987)		214,878		426,255		(8,169)		418,086
Selling, general, and administrative	129,118		(3,987)		125,131		258,981		(8,169)		250,812


	Three Months Ended September 30, 2024						Nine Months Ended September 30, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	92,856	$	4,235	$	97,091	$	280,088	$	12,404	$	292,492
Gross profit	225,264		(4,235)		221,029		651,519		(12,404)		639,115
Selling, general, and administrative	131,661		(4,235)		127,426		390,642		(12,404)		378,238

The following tables present a summary of the correction to the impacted Cardiopulmonary disaggregated segment income table line items in “Note 17. Geographic and Segment Information” and “Note 10. Geographic and Segment Information” previously included in the 2024 Annual Report on Form 10-K and in the unaudited March 31, 2025 Quarterly Report on Form 10-Q, respectively (in thousands):


	Twelve Months Ended December 31, 2024						Twelve Months Ended December 31, 2023
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	316,937	$	17,389	$	334,326	$	290,929	$	15,430	$	306,359
Selling, general, and administrative	217,136		(17,389)		199,747		207,001		(15,430)		191,571


	Three Months Ended March 31, 2025						Three Months Ended March 31, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	80,399	$	4,521	$	84,920	$	72,097	$	4,182	$	76,279
Selling, general, and administrative	58,480		(4,521)		53,959		50,745		(4,182)		46,563